Published in Chem Biol on November 24, 2010
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med (2013) 2.19
Chemical probes of endocannabinoid metabolism. Pharmacol Rev (2013) 1.68
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Modulating the endocannabinoid system in human health and disease--successes and failures. FEBS J (2013) 1.59
Amygdala FAAH and anandamide: mediating protection and recovery from stress. Trends Pharmacol Sci (2013) 1.27
Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? Br J Pharmacol (2012) 1.00
Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction. Pharmacol Ther (2013) 0.92
The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing. Neuroscience (2011) 0.90
Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol (2012) 0.89
Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2013) 0.87
Sulfonyl fluoride inhibitors of fatty acid amide hydrolase. J Med Chem (2012) 0.80
The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. Br J Pharmacol (2016) 0.79
Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids. Neuropsychopharmacology (2015) 0.78
Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis. JCI Insight (2016) 0.77
Approximating protein flexibility through dynamic pharmacophore models: application to fatty acid amide hydrolase (FAAH). J Chem Inf Model (2011) 0.76
Effects of fatty acid amide hydrolase (FAAH) inhibitors on working memory in rats. Psychopharmacology (Berl) (2015) 0.76
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants. Curr Neuropharmacol (2015) 0.75
Chronic inhibition of fatty acid amide hydrolase by URB597 produces differential effects on cardiac performance in normotensive and hypertensive rats. Br J Pharmacol (2017) 0.75
CB1 receptor activation in the rat paraventricular nucleus induces bi-directional cardiovascular effects via modification of glutamatergic and GABAergic neurotransmission. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Fatty-acid-binding protein inhibition produces analgesic effects through peripheral and central mechanisms. Mol Pain (2017) 0.75
Phytoestrogens enhance the vascular actions of the endocannabinoid anandamide in mesenteric beds of female rats. Int J Hypertens (2012) 0.75
Sulfonyl fluorides as privileged warheads in chemical biology. Chem Sci (2015) 0.75
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 8.99
Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med (2002) 7.72
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The sympathetic control of blood pressure. Nat Rev Neurosci (2006) 6.44
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol (2003) 3.17
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol (1993) 2.98
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem (1986) 2.95
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 2.82
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation (2004) 2.15
Cannabinoid receptor signaling. Handb Exp Pharmacol (2005) 2.00
Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity. Biochemistry (2007) 1.90
Comparative influence of load versus inotropic states on indexes of ventricular contractility: experimental and theoretical analysis based on pressure-volume relationships. Circulation (1987) 1.90
Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J Pharmacol Exp Ther (1997) 1.87
Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol (2005) 1.76
Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet (2004) 1.68
Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. Neuropharmacology (2007) 1.68
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 1.54
Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension (1996) 1.46
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem (2008) 1.30
Impairment of sympathetic baroreceptor reflexes in obese Zucker rats. Am J Physiol Heart Circ Physiol (2007) 1.22
Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am J Physiol Heart Circ Physiol (2003) 1.20
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun (1997) 1.14
Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukot Essent Fatty Acids (1995) 1.10
FAAH deficiency promotes energy storage and enhances the motivation for food. Int J Obes (Lond) (2009) 1.05
The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn Schmiedebergs Arch Pharmacol (2003) 1.03
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem (2007) 1.01
Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies. Int Rev Psychiatry (2009) 0.96
Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat. Clin Exp Pharmacol Physiol (1999) 0.90
The cannabinergic system as a target for anti-inflammatory therapies. Curr Top Med Chem (2006) 0.89
Differential endocannabinoid regulation of baroreflex-evoked sympathoinhibition in normotensive versus hypertensive rats. Auton Neurosci (2009) 0.88
Overexpression of Gi-proteins precedes the development of DOCA-salt-induced hypertension: relationship with adenylyl cyclase. Cardiovasc Res (1998) 0.88
Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br J Pharmacol (2000) 0.86
Enhanced expression of Gi-protein precedes the development of blood pressure in spontaneously hypertensive rats. J Mol Cell Cardiol (1997) 0.85
Enhanced expression of Gialpha protein and adenylyl cyclase signaling in aortas from 1 kidney 1 clip hypertensive rats. Can J Physiol Pharmacol (2006) 0.84
A human fatty acid amide hydrolase (FAAH) functional gene variant is associated with lower blood pressure in young males. Am J Hypertens (2008) 0.82
Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98
Phaeochromocytoma. Lancet (2005) 8.73
Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. Nature (2012) 7.87
Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature (2007) 7.12
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gut microbiomes of Malawian twin pairs discordant for kwashiorkor. Science (2013) 6.98
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A (2008) 6.53
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 6.20
Profiling enzyme activities in vivo using click chemistry methods. Chem Biol (2004) 5.97
Augmented Wnt signaling in a mammalian model of accelerated aging. Science (2007) 5.62
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A (2008) 5.48
Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell (2010) 5.47
Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol (2008) 5.32
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne [3 + 2] cycloaddition. J Am Chem Soc (2003) 4.92
Biochemical diagnosis of pheochromocytoma: which test is best? JAMA (2002) 4.84
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Regulation of homologous recombination in eukaryotes. Annu Rev Genet (2010) 4.33
miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer (2008) 4.09
Superoxide flashes in single mitochondria. Cell (2008) 4.08
Quantitative reactivity profiling predicts functional cysteines in proteomes. Nature (2010) 4.04
Global mapping of the topography and magnitude of proteolytic events in apoptosis. Cell (2008) 3.64
Identification of protein pheromones that promote aggressive behaviour. Nature (2007) 3.55
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science (2011) 3.48
The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol (2013) 3.39
Structure and function of fatty acid amide hydrolase. Annu Rev Biochem (2005) 3.33
Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab (2005) 3.32
Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol (2003) 3.17
Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest (2008) 3.13
Large-scale profiling of protein palmitoylation in mammalian cells. Nat Methods (2009) 3.13
MiR-218 inhibits invasion and metastasis of gastric cancer by targeting the Robo1 receptor. PLoS Genet (2010) 3.12
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci (2010) 3.11
Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochemistry (2004) 3.10
An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol (2009) 3.05
Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation (2006) 3.01
A streamlined platform for high-content functional proteomics of primary human specimens. Nat Methods (2005) 3.00
Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther (2004) 2.99
An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem Biol (2006) 2.98
Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol (2005) 2.98
Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain (2004) 2.94
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med (2008) 2.91
Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab (2008) 2.91
Activation of the peripheral endocannabinoid system in human obesity. Diabetes (2005) 2.90
Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci (2008) 2.87
Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci (2003) 2.84
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 2.82
Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol (2007) 2.81
Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci (2007) 2.78
Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab (2012) 2.76
Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N Engl J Med (2012) 2.74
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Mechanism-based profiling of enzyme families. Chem Rev (2006) 2.66
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol (2007) 2.60
Prevalence of cardiovascular disease risk factor in the Chinese population: the 2007-2008 China National Diabetes and Metabolic Disorders Study. Eur Heart J (2011) 2.57
The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest (2004) 2.52
Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci U S A (2002) 2.52
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2009) 2.51
Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science (2002) 2.50
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest (2013) 2.50
Minireview: GNAS: normal and abnormal functions. Endocrinology (2004) 2.50
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations. J Clin Oncol (2011) 2.49
Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol (2009) 2.48
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood (2010) 2.48
Etiology of diarrhea in Bangladeshi infants in the first year of life analyzed using molecular methods. J Infect Dis (2013) 2.43
Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab (2007) 2.41
A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell (2009) 2.41
Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes (2006) 2.40
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nat Neurosci (2010) 2.37
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32